Life science firm Jubilant & Sanofi collaborate on CNS therapeutics
Category: #health  By Mateen Dalal  Date: 2019-02-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Life science firm Jubilant & Sanofi collaborate on CNS therapeutics

Jubilant will deliver Sanofi drug discovery services with its integrated drug discovery platform.

The Bengaluru-based arm of the reputed Jubilant Life Sciences, Jubilant Biosys, has apparently declared that it has signed an integrated drug discovery collaboration with pharmaceutical company. Credible reports cite that the collaboration will focus on the domain of CNS therapeutics.

As per sources familiar with the matter, the debut collaboration with Sanofi had commenced back in 2016, targeted toward the discovery and development of small molecule inhibitors for numerous targets in metabolic disorders therapeutics.

An official press release from Jubilant Biosys claims that the collaboration in question is basically aimed to discover therapeutic small molecules which will be addressing unmet needs in neurological diseases. Jubilant Biosys reportedly, will be providing Sanofi drug discovery services with its integrated drug discovery platform in a bid to identify lead candidates.

Rita Balice-Gordon, Global Head, Rare and Neurologic Diseases Therapeutic Area, Sanofi, has been reported to state that the company has been earnestly looking forward to collaborating with Jubilant. The new partnership aptly demonstrates Sanofi’s dedicated commitment toward striving to discover novel medicines which can target neurological diseases, the needs of which are currently unmet around the globe, Balice-Gordon elaborates.

Speaking on the partnership, Marcel Velterop, President, Jubilant Drug Discovery Services & CDMO, claimed that the company is rather privileged and delighted to have been selected once more by Sanofi in order to contribute toward driving innovation to the clinic. The current achievement is undeniably testifies the high quality science and capability that Jubilant has built since the past decade, says Velterop, adding that the collaboration is perfectly aligned with Jubilant’s growth strategy and the company is totally committed to expand its world-class integrated, drug discovery capabilities.

For the record, Jubilant Biosys boasts of having depicted considerable expertise in numerous therapeutic domains, inclusive of Metabolic Disorders, Pain & Inflammation, CNS, Oncology, and many more.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...